1. Search Result
Search Result
Results for "

Aβ aggregation

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141661

    Amyloid-β Neurological Disease
    Aβ/tau aggregation-IN-1 is a potent 1-42 β-sheets formation and tau aggregation inhibitor. The KD values of Aβ/tau aggregation-IN-1 with 1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .
    <em>Aβ</em>/tau <em>aggregation</em>-IN-1
  • HY-153430

    Amyloid-β Neurological Disease
    Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC50 of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .
    <em>Aβ</em>/tau <em>aggregation</em>-IN-3
  • HY-150003

    Cholinesterase (ChE) Amyloid-β Neurological Disease
    Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC50 value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .
    <em>Aβ</em>1–42 <em>aggregation</em> inhibitor 1
  • HY-149272

    Tau Protein Amyloid-β Cholinesterase (ChE) Neurological Disease
    tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and 40 aggregation inhibitor with IC50s of 1.8 μM and 1.3 μM, respectively .
    tau/<em>Aβ</em>40 <em>aggregation</em>-IN-1
  • HY-162093

    Amyloid-β Neurological Disease
    Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of? Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .
    <em>Aβ</em>1–42 <em>aggregation</em> inhibitor 2
  • HY-149583

    Amyloid-β Neurological Disease
    Aβ-IN-8 (compound 7e) is a potent inhibitor of the aggregation .
    Aβ-IN-8
  • HY-149582

    Amyloid-β Neurological Disease
    Aβ-IN-7 (compound 5a) is a potent inhibitor of the aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .
    Aβ-IN-7
  • HY-147938

    Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE-IN-19 (compound A15) is a highly potent AChE inhibitor with an IC50 value of 0.56 μM, also inhibits aggregation. AChE-IN-19 has potent neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE-IN-19 can be used for researching Alzheimer's disease .
    AChE-IN-19
  • HY-147659

    Cholinesterase (ChE) Beta-secretase ROS Kinase Neurological Disease
    AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .
    AChE/BChE/BACE-1-IN-2
  • HY-147658

    Cholinesterase (ChE) Beta-secretase ROS Kinase Neurological Disease
    AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .
    AChE/BChE/BACE-1-IN-1
  • HY-150585

    Amyloid-β Cholinesterase (ChE) Tau Protein Neurological Disease
    BuChE-IN-5 (compound 25b) is a potent BuChE inhibitor with an IC50 value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation and tau protein in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease .
    BuChE-IN-5
  • HY-155305

    Cholinesterase (ChE) Beta-secretase GABA Receptor Neurological Disease
    BuChE-IN-9 (compound 22a) is a potent equine serum-derived BuChE (eqBuChE) inhibitor with an IC50 of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties .
    BuChE-IN-9
  • HY-149340

    Cholinesterase (ChE) Neurological Disease
    PD07 is an orally active AChE inhibitor (IC50: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC50: 13.42 μM), and Aβ1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC50: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .
    PD07
  • HY-147859

    Amyloid-β Neurological Disease
    BChE-IN-8 (compound 20) is an orally active, potent and BBB-penetrated BChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.15 nM (eqBChE, equine serum BChE) and 45.2 nM (hBChE), respectively. High stability of BChE-IN-8 contributes to significantly improved blood concentration and tissue exposure. BChE-IN-8 can exert neuro-protecting and cognition improving properties through multiple modulations, including cholinergic system, Aβ aggregation, neuropeptide levels. BChE-IN-8 can be used for Alzheimer's disease (AD) research .
    BChE-IN-8
  • HY-112636

    Amyloid-β Others
    Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice .
    Astrophloxine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: